$ENTA

ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals is a biotechnology company that discovers and develops small molecule drugs for virology and immunology. Its wholly owned programs include clinical-stage candidates for respiratory syncytial virus, zelicapavir and EDP-323, and preclinical oral inhibitor programs targeting KIT and STAT6 for inflammatory diseases. It also has clinical-stage programs for SARS-CoV-2 and hepatitis B virus. Enanta discovered glecaprevir, which AbbVie combines with pibrentasvir in the HCV treatments marketed as MAVYRET in the U.S. and MAVIRET outside the U.S. Enanta earns royalties on sales of this combination and receives cash flows from the portion of future royalties it retains. Its headquarters are in Watertown, Massachusetts.

0
1
2

No SEC Form 4 filings for $ENTA in the last 30 days.

See all $ENTA insider activity →
Med

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026 • Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q

Enanta Pharmaceuticals (ENTA) Reports FY2026 Net Loss of $68.2M

Enanta Pharmaceuticals reported FY2026 revenue of $63.0M, down from $65.3M in FY2025, and a net loss of $68.2M, or $2.35 per share, improving from a $81.9M loss in FY2025. The company had $194.5M in cash and expects funding into fiscal 2029. Key catalysts include Q1 2027 LOTUS topline data and 2027 RESOLVE Phase 2b results.

Enanta Pharmaceuticals, Inc. filed a patent infringement action in the Unified Patent Court of the European Union against Pfizer Inc. and certain of its…

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, Enanta Pharmaceuticals, Inc. (the “Company”) filed a patent infringement action in the Unified Patent Court (the “UPC”) of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability

ENTA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ENTA (ENANTA PHARMACEUTICALS INC). Coverage has skewed bearish: 0 bullish, 1 neutral, and 2 bearish.

Recent ENTA coverage spans earnings, regulation and corporate actions.

What's driving ENTA

  • Near-term sentiment likely improves on clearer RSV catalyst timing, but royalty revenue softness and higher interest expense temper the earnings read-through.

    SEC EDGAR 8-K · Nov 16, 2026

  • The disclosed FY2026 loss and funding runway shape near-term risk appetite and valuation for this clinical-stage RSV pipeline company.

    tradingview.com · Nov 16, 2026

  • The patent invalidation removes Enanta's legal leverage against Pfizer, likely hurting its valuation.

    SEC EDGAR 8-K · Oct 29, 2026

  • Leadership transition may cause short‑term stock pressure as investors assess succession and strategic direction.

    tradingview.com · Oct 28, 2026

  • Leadership transition may create short‑term uncertainty and potential downside pressure on the stock.

    SEC EDGAR 8-K · Oct 28, 2026

AlphAI scores every news story that mentions ENTA with an AI model for sentiment and relevance, and aggregates insider trades from ENANTA PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ENTA

Score
$ENTAMedEarnings

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026 • Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q

Enanta Pharmaceuticals (ENTA) Reports FY2026 Net Loss of $68.2M

Enanta Pharmaceuticals reported FY2026 revenue of $63.0M, down from $65.3M in FY2025, and a net loss of $68.2M, or $2.35 per share, improving from a $81.9M loss in FY2025. The company had $194.5M in cash and expects funding into fiscal 2029. Key catalysts include Q1 2027 LOTUS topline data and 2027 RESOLVE Phase 2b results.

Enanta Pharmaceuticals, Inc. filed a patent infringement action in the Unified Patent Court of the European Union against Pfizer Inc. and certain of its…

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, Enanta Pharmaceuticals, Inc. (the “Company”) filed a patent infringement action in the Unified Patent Court (the “UPC”) of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability

$ENTALowExec change· retired

ENANTA PHARMACEUTICALS INC (ENTA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership WATERTOWN, Mass., October 28, 2026 – Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company

$ENTAMedEarnings

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 • Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027 • On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Ri

Enanta Was First To File. Pfizer Still Won. The Difference Was One Digit.

The US Federal Circuit affirmed that every claim in Enanta Pharmaceuticals’ patent on a coronavirus protease inhibitor is invalid in Enanta Pharmaceuticals, Inc. v. Pfizer Inc. (Fed. Cir. June 23, 2026). The court said Enanta’s provisional did not disclose the relevant C1 alkyl range, so Pfizer’s April 6, 2021 nirmatrelvir (Paxlovid) presentation was prior art. Paxlovid earned about $19B in 2022.

Federal Circuit Decision: When A Typo Costs A Patent Its Priority Date

The Federal Circuit, in Enanta Pharmaceuticals v. Pfizer, held Enanta’s patent could not claim priority to an earlier provisional filing because the provisional described a C2-C12 alkyl range, while the issued claims covered C1-C12. Pfizer’s intervening disclosure of nirmatrelvir (Paxlovid) was treated as prior art, anticipating and invalidating Enanta’s claims under 35 U.S.C. §112.

Related tickers